EVUSHELD: Protection for the Immunocompromised

EVUSHELD (tixagevimab & cilgavimab) is designed to offer protection from COVID-19 infections in patients who cannot mount an adequate immune response from COVID-19 vaccination (or for patients who cannot receive the vaccine for medical reasons).

EVUSHELD is specifically designed for patients that are immunocompromised.  Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include but are not limited to:

  •  Active treatment for solid tumor and hematologic malignancies
  • Receipt of solid-organ transplant and taking immunosuppressive therapy
  • Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
  • Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
  • Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites,  transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents)

Want an EVUSHELD injection?  Fill out the form below:

Who is eligible for EVUSHELD?

Patients who receive EVUSHELD must be at least 12 years of age and weigh 40 kg or more.

Patients that are undergoing cancer treatment or are taking medications for treatment of Multiple Sclerosis (MS), Rheumatoid Arthritis, Crohn’s Disease, and to prevent organ transplant rejection all qualify.

Medications for MS include:

  • Ocrevus (ocrelizumab)
  • Kesimpta (ofatumumab)
  • Aubagio (teriflunomide)
  • Tysabri (natalizumab)
  • Lemtrada (alemtuzumab)

Medications that are TNF inhibitors that would qualify include:

  • Enbrel (etanercept)
  • Remicade (infliximab)
  • Humira (adalimumab)
  • Cimzia (certolizumab pegol)
  • Simponi (golimumab)

Medications commonly used for transplant rejection:

  • Prograf (tacrolimus)
  • Neoral (cyclosporine)
  • Imuran (azathioprine)
  • Rapamune (sirolimus, rapamycin)
  • Cellcept (mycophenolate mofetil)

If you are unsure whether you qualify or not, please do not hesitate to fill out the above form and we will have one of our providers contact you to discuss.

Learn more by watching our videos below:

Contact Atracare Health to schedule an appointment to discuss Covid 19 preventative options with your primary care doctor. Follow us on Facebook  and/or Instagram to get updates as they become available to our community in Southern Delaware.

Learn more about the Covid 19 Treatment options available through Atracare Health >

0 New comments

Leave a Reply

Your email address will not be published.

Latest News and Clinic Information

We are your partner in health. Stay up to date with latest news and information.

Am I Just Burned Out or is it Compassion Fatigue?

Though it is commonly associated with nursing or social work, compassion fatigue can impact anyone in the helping professions. Teachers, therapists, first responders, and even pastors are just some of the professions at risk of developing this mental health issue. But what is it, exactly, and how would you know if it is happening to you?

Read More

Three Things to Ask Your Next Therapist Before Making An Appointment

Looking for the right therapist can be a daunting task, especially if you aren’t sure what questions to ask before booking your first appointment. People seek therapy for a variety of reasons, so it’s important to connect with the therapist equipped with the right toolset to meet your unique needs.

Read More

We are now Atracare

As we grow, we are moving away from being just a name and more towards our mark that exemplifies the care that patients receive. While we need to change our name, we want to be more than just a name. Instead we strive to be a brand that exemplifies our care and the “A plus” efforts we make to serve and treat our community which our logo represents.

Read More